phrykt

Passage BIO, Inc. (PASG): who owns it and who trades it

As of Nov 12, 2026, PASG insiders reported 1 purchase worth $206K in the last 12 months. The largest buyer was Weston Nichols (10% owner), with $206K. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 12, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Passage BIO

From the latest filings

Overall: about as much buying as selling. Famous investors mostly sold. Insiders mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, PASG insiders reported $206K of open-market purchases and $0 of sales.

Purchases, 12 months
$206K
1 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Jun 25, 2026
Filed Jun 29, 2026

Purchases and sales by month

$206K$206KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jun 25, 2026Weston Nichols +110% ownerPurchase50,055$4.12$206KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Weston Nichols10% owner$206K–Jun 25, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PASG short interest

Low short interest. 1.5% of PASG shares are sold short: about 1 share in 65. Over the last 12 reports the number of shares short went down 70%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 49,551 PASG shares were sold short, 1.5% of the shares outstanding, down 28.1% from the report before. At the average daily volume of 12,434 shares, buying them all back would take about 4.0 trading days (days to cover).

Shares short, % of all shares

1.54%May 15Oct 305.60%

Days to cover

4.0May 15Oct 3014.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202649,5511.54%-28%12,4344.0
Oct 15, 202668,9172.14%-24%19,8363.5
Sep 30, 202690,8402.82%-6%24,7393.7
Sep 15, 202697,0083.01%-5%30,3153.2
Aug 31, 2026101,6383.16%-26%19,6005.2
Aug 14, 2026136,9354.26%-12%10,43513.1
Jul 31, 2026155,8374.86%+25%34,4564.5
Jul 15, 2026124,6283.89%+9%48,2392.6
Jun 30, 2026114,1933.56%+23%257,1271.0
Jun 15, 202692,5812.89%-24%36,1792.6
May 29, 2026121,9843.80%-25%33,5473.6
May 15, 2026162,6265.07%+12%87,5321.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Passage BIO company events

Passage BIO filed 10 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, control, job cuts). The latest was on Nov 6, 2026.

  1. Nov 6, 2026LeadershipPassage Bio, Inc. held a Special Meeting of Stockholders. Filing
  2. Sep 3, 2026AgreementAmended and Restated Merger Agreement As previously disclosed, on June 24, 2026, Passage Bio, Inc., Peregrine Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company, and Remix Therapeutics, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger… Filing
  3. Jun 24, 2026ControlThe information set forth in Item 1.01 and in Item 5.02 is incorporated by reference into this Item 5.01. Filing
  4. May 27, 2026AgreementEnded an important agreement. Filing
  5. May 26, 2026VoteReported shareholder vote results. Filing
  6. Apr 28, 2026Job cutsAnnounced job cuts or other exit costs. Filing
  7. Apr 20, 2026AnnouncementShared information with investors. Filing
  8. Mar 10, 2026AgreementEnded an important agreement. Filing
  9. Mar 3, 2026ResultsReleased financial results. Filing
  10. Jan 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Passage BIO financials

Famous investors that hold PASG

1 of the 50 well-known investors we track reported holding PASG in their latest 13F filing. The largest position is Jim Simons's, worth $211K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 202646,892$211K0.0%-2%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Passage BIO, Inc. (PASG) stock

Are PASG insiders buying or selling?

In the last 12 months, PASG insiders reported 1 open-market purchase worth $206K and no sales. The latest trade was on Jun 25, 2026. See every trade.

What is the short interest in PASG?

As of Oct 30, 2026, 49,551 PASG shares were sold short, 1.5% of the shares outstanding, down 28.1% from the report before. At the average daily volume of 12,434 shares, buying them all back would take about 4.0 trading days (days to cover). See the history.

Which famous investors hold PASG?

1 of the 50 well-known investors we track reported PASG in their latest 13F filing, including Jim Simons. The largest position is worth $211K. See all holders.

Executive pay

Passage BIO's chief executive was paid a total of $1.5M for the year ended Dec 31, 2025, down 9% from $1.6M the year before. In the last 12 months, Passage BIO's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$1.5MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1.5MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$723KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.